Top

Published in:

Open Access 01-12-2016 | Editorial

The up-rise in e-cigarette use – friend or foe?

Authors: Bo Lundbäck, Paraskevi Katsaounou, Jan Lötvall

Published in: Respiratory Research | Issue 1/2016

Excerpt

Following the millennium shift, the market for e-cigarettes has expanded logarithmically, and today there are hundreds of e-cigarette products and thousands of flavor variations. This increase in e-cigagette use contrasts to a major and continuing decrease in cigarette smoking seen in most westernized countries for some decades [1]. It seems that the marketing of e-cigarettes is less active in middle and low level income countries, as exemplified in a paper from Egypt in this issue of Respiratory Research [2]. …

Gibson J, Loddenkemper R, Sibille Y, Lundbäck B. The European Lung White Book. Sheffield: the European Respiratory Society; 2013.

Omaima I Abo-Elkheir OI, Sobh E. Knowledge about electronic cigarettes and its perception: a community survey, Egypt. Respir Res. 2016. In press.

McNeill A, Brose LS, Calder R, et al. E-cigarettes: an evidence update: a report commissioned by Public Health England. Public Health England. 2015.

McKee M, Capewell S. Evidence about electronic cigarettes: a foundation built on rock or sand? BMJ. 2015;351:h4863.CrossRefPubMed

E-cigarettes: Public Health England’s evidence-based confusion. Editorial. Lancet. 2015;386(9996):829.

Vardavas CI, Filippidis FT, Agaku IT. Determinants and prevalence of e-cigarette use throughout the European Union: a secondary analysis of 26 566 youth and adults from 27 Countries. Tob Control. 2015;24(5):442–8.CrossRefPubMed

Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med. 2016 (E-pub January 16).

Sherratt FC, Newson L. Electronic cigarettes: a survey of perceived patient use and attitudes among members of The British Thoracic Oncology Group. Respir Res. 2016.

McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. Electronic cigarettes for smoking cessation and reduction. The Cohrane Collaboration. 2014.

10.

Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, Walker N. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013;382(9905):1629–37.CrossRefPubMed

11.

Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, Polosa R. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2013;8(6):e66317.CrossRefPubMedPubMedCentral

12.

Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;31:5.

13.

Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2012;10:CD008286.PubMed

14.

Gonzales D, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55.CrossRefPubMed

15.

Jorenby DE et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63.CrossRefPubMed

16.

Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J. 2004;23:327–33.CrossRefPubMed

17.

Goniewicz ML, Knysak J, Gawron M, Kosmider L, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014;23:133–9.CrossRefPubMed

18.

Franck C, Filion KB, Kimmelman J, Grad R, Eisenberg M. Ethical considerations of e-cigarette use for tobacco harm reduction. Respir Res. 2016.

19.

Bahl V, Lin S, Xu N, Davis B, Wang YH, Talbot P. Comparison of electronic cigarette refill fluid cytotoxicity using embryonic and adult models. Reprod Toxicol. 2012;34:529–37.CrossRefPubMed

20.

Cara L. Sherwood CL, Boitano S. Airway epithelial cell exposure to distinct e-cigarette liquid flavorings reveals toxicity thresholds and activation of CFTR by the chocolate flavoring 2,5-dimethypyrazine. Respir Res. 2016.

21.

Higham A, Rattray NJW, Dewhurst JA, Trivedi D, et al. Electronic Cigarette Exposure Triggers Neutrophil Inflammatory Responses. Respir Res. 2016.

22.

Vardavas CI, Anagnostopoulos N, Kougias M, Evangelopoulou V, Connolly GN, Behrakis PK. Short-term pulmonary effects of using an electronic cigarette: impact on respiratory flow resistance, impedance, and exhaled nitric oxide. Chest. 2012;141:1400–6.CrossRefPubMed

23.

Durmowicz EL. The impact of electronic cigarettes on the paediatric population. Tob Control. 2014;23(S2):41–6.CrossRef

24.

Schraufnage DE, Blasi F, Drummond MB, Lam DC, et al. Electronic Cigarettes: a position statement of the Forum of International Respiratory Societies. Am J Respir Crit Care Med. 2014;190(6):611–8.CrossRef

Title: The up-rise in e-cigarette use – friend or foe?
Authors: Bo Lundbäck
Paraskevi Katsaounou
Jan Lötvall
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Respiratory Research / Issue 1/2016
Electronic ISSN: 1465-993X
DOI: https://doi.org/10.1186/s12931-016-0371-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The up-rise in e-cigarette use – friend or foe?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2016

Differences in systemic adaptive immunity contribute to the ‘frequent exacerbator’ COPD phenotype

Cigarette smoke alters the ability of human dendritic cells to promote anti-Streptococcus pneumoniae Th17 response

Diagnostic accuracy of methacholine challenge tests assessing airway hyperreactivity in asthmatic patients - a multifunctional approach

The genetic and epigenetic landscapes of the epithelium in asthma

Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies

Ethical considerations of e-cigarette use for tobacco harm reduction

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page